These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 34739075)

  • 21. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.
    Pollyea DA; Pratz KW; Wei AH; Pullarkat V; Jonas BA; Recher C; Babu S; Schuh AC; Dail M; Sun Y; Potluri J; Chyla B; DiNardo CD
    Clin Cancer Res; 2022 Dec; 28(24):5272-5279. PubMed ID: 36007102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Venetoclax exposure-efficacy and exposure-safety relationships in patients with treatment-naïve acute myeloid leukemia who are ineligible for intensive chemotherapy.
    Brackman D; Eckert D; Menon R; Salem AH; Potluri J; Smith BD; Wei AH; Hayslip J; Miles D; Mensing S; Gopalakrishnan S; Zha J
    Hematol Oncol; 2022 Apr; 40(2):269-279. PubMed ID: 35043428
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Venetoclax and Azacitidine in Acute Myeloid Leukemia Compared to Azacitidine Monotherapy: Real-World Experience.
    Baba Y; Hida N; Sambe T; Abe M; Kabasawa N; Sakai H; Yoshimura K; Fukuda T
    Anticancer Res; 2024 May; 44(5):2003-2007. PubMed ID: 38677735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.
    He H; Wen X; Zheng H
    Hematology; 2024 Dec; 29(1):2343604. PubMed ID: 38703055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.
    Wei AH; Strickland SA; Hou JZ; Fiedler W; Lin TL; Walter RB; Enjeti A; Tiong IS; Savona M; Lee S; Chyla B; Popovic R; Salem AH; Agarwal S; Xu T; Fakouhi KM; Humerickhouse R; Hong WJ; Hayslip J; Roboz GJ
    J Clin Oncol; 2019 May; 37(15):1277-1284. PubMed ID: 30892988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Short-term efficacy of venetoclax combined with azacitidine in acute myeloid leukemia: a single-institution experience].
    Yu WJ; Jia JS; Wang J; Tang FF; Gong LZ; Liu XH; Zhu XL; Zhao XS; Huang XJ; Jiang H
    Zhonghua Xue Ye Xue Za Zhi; 2022 Feb; 43(2):134-140. PubMed ID: 35381674
    [No Abstract]   [Full Text] [Related]  

  • 28. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
    Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
    Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1-2 study.
    Bazinet A; Darbaniyan F; Jabbour E; Montalban-Bravo G; Ohanian M; Chien K; Kadia T; Takahashi K; Masarova L; Short N; Alvarado Y; Yilmaz M; Ravandi F; Andreeff M; Kanagal-Shamanna R; Ganan-Gomez I; Colla S; Qiao W; Huang X; McCue D; Mirabella B; Kantarjian H; Garcia-Manero G
    Lancet Haematol; 2022 Oct; 9(10):e756-e765. PubMed ID: 36063832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
    Kadia TM; Reville PK; Wang X; Rausch CR; Borthakur G; Pemmaraju N; Daver NG; DiNardo CD; Sasaki K; Issa GC; Ohanian M; Montalban-Bravo G; Short NJ; Jain N; Ferrajoli A; Bhalla KN; Jabbour E; Takahashi K; Malla R; Quagliato K; Kanagal-Shamanna R; Popat UR; Andreeff M; Garcia-Manero G; Konopleva MY; Ravandi F; Kantarjian HM
    J Clin Oncol; 2022 Nov; 40(33):3848-3857. PubMed ID: 35704787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
    Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
    Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.
    Murthy GSG; Saliba AN; Szabo A; Harrington A; Abedin S; Carlson K; Michaelis L; Runaas L; Baim A; Hinman A; Maldonado-Schmidt S; Venkatachalam A; Flatten KS; Peterson KL; Schneider PA; Litzow M; Kaufmann SH; Atallah E
    Haematologica; 2024 Sep; 109(9):2864-2872. PubMed ID: 38572562
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia.
    Winters AC; Gutman JA; Purev E; Nakic M; Tobin J; Chase S; Kaiser J; Lyle L; Boggs C; Halsema K; Schowinsky JT; Rosser J; Ewalt MD; Siegele B; Rana V; Schuster S; Abbott D; Stevens BM; Jordan CT; Smith C; Pollyea DA
    Blood Adv; 2019 Oct; 3(20):2911-2919. PubMed ID: 31648312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Venetoclax plus cytarabine and azacitidine in relapsed/refractory AML: An open-label, single-arm, phase 2 study.
    You L; Liu Y; Mai W; Xie W; Zhou D; Mao L; Chen L; Zhou X; Ma L; Zheng X; Wei J; Lou Y; Ye X; Tong H; Jin J; Meng H
    Eur J Cancer; 2024 May; 202():113979. PubMed ID: 38471289
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia.
    Patel KK; Zeidan AM; Shallis RM; Prebet T; Podoltsev N; Huntington SF
    Blood Adv; 2021 Feb; 5(4):994-1002. PubMed ID: 33591323
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The Efficacy and Safety of Venetoclax Combined with Azacitidine in the Treatment of Adult Patients with Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy].
    Wang KY; Fan BR; Zhang QW; Han MR; Ge XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):342-346. PubMed ID: 38660834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Efficacy of venetoclax combined azacitidine in newly diagnosed acute myeloid leukemia unfit for standard chemotherapy: a single center experience].
    Sun L; Ye SJ; Zhou N; Han XZ; Qi JX; Liu XJ; Luo JM; Yang L
    Zhonghua Xue Ye Xue Za Zhi; 2022 Oct; 43(10):826-832. PubMed ID: 36709196
    [No Abstract]   [Full Text] [Related]  

  • 38. Venetoclax for the treatment of elderly or chemotherapy-ineligible patients with acute myeloid leukemia: a step in the right direction or a game changer?
    Agarwal S; Kowalski A; Schiffer M; Zhao J; Bewersdorf JP; Zeidan AM
    Expert Rev Hematol; 2021 Feb; 14(2):199-210. PubMed ID: 33459064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Venetoclax combined with hypomethylating agents or low-dose cytarabine as induction chemotherapy for patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy: a systematic review and meta-analysis.
    Qin Y; Kuang P; Liu T
    Clin Exp Med; 2023 Jun; 23(2):219-227. PubMed ID: 35066728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 6-month follow-up of VIALE-C demonstrates improved and durable efficacy in patients with untreated AML ineligible for intensive chemotherapy (141/150).
    Wei AH; Panayiotidis P; Montesinos P; Laribi K; Ivanov V; Kim I; Novak J; Stevens DA; Fiedler W; Pagoni M; Bergeron J; Ting SB; Hou JZ; Anagnostopoulos A; McDonald A; Murthy V; Yamauchi T; Wang J; Chyla B; Sun Y; Jiang Q; Mendes W; Hayslip J; DiNardo CD
    Blood Cancer J; 2021 Oct; 11(10):163. PubMed ID: 34599139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.